Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
This is used to treat central diabetes insipidus and bedwetting
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Subscribe To Our Newsletter & Stay Updated
